FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:942-955 March 2, 2006 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Substantial advances have occurred in the understanding of some of the central mechanisms underlying the inflammation, demyelination, and neurodegeneration that occur in multiple sclerosis since the topic was last reviewed in the Journal.¹ Accordingly, the available clinical strategies for the management of the disease have widened (Table 1).² However, the treatment options for the disease are most effective during the relapsing–remitting phase (relapsing–remitting multiple sclerosis), which is characterized by clinical exacerbations, inflammation, and evidence of plaques within the brain and spinal cord on magnetic resonance imaging (MRI). Less understood are factors that promote the transition from relapsing–remitting . . . [Full Text of this Article]

Evolution of the Multiple Sclerosis Plaque

Cells Involved in the Pathogenesis of the Multiple Sclerosis Plaque

T Cells

B Cells

Other Immune Cells

Disease Initiation and Pathogenesis

Pathogenesis of Multiple Sclerosis Lesions Revisited

Neuropathology

Classification of Lesions — Stages or Types?

Axonal Dysfunction and Channelopathy

Excitatory Amino Acid Receptors and Neurodegeneration

Growth Factors

The Enigma of Remyelination

A Role for Oligodendrocyte Apoptosis?

The Plaque Edge — A Fine Line

Radiographic Measures of the Lesion's Pathological Character

Prospects for Characterizing the Evolution and Progression of Multiple Sclerosis

Source Information

From the Departments of Neurology and Ophthalmology (E.M.F.), and the Department of Neurology and the Center for Immunology (M.K.R.), University of Texas Southwestern Medical Center at Dallas, Dallas; and the Division of Neuropathology, the Department of Pathology and Neurology, Albert Einstein College of Medicine, Bronx, N.Y. (C.S.R.).

Address reprint requests to Dr. Frohman at the Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390, or at elliot.frohman@utsouthwestern.edu.

This article has been cited by other articles:

• Bittner, S., Meuth, S. G., Gobel, K., Melzer, N., Herrmann, A. M., Simon, O. J., Weishaupt, A., Budde, T., Bayliss, D. A., Bendszus, M., Wiendl, H. (2009). TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain 0: awp163v1-awp163 [Abstract] [Full Text]  
• McCandless, E. E., Budde, M., Lees, J. R., Dorsey, D., Lyng, E., Klein, R. S. (2009). IL-1R Signaling within the Central Nervous System Regulates CXCL12 Expression at the Blood-Brain Barrier and Disease Severity during Experimental Autoimmune Encephalomyelitis. J. Immunol. 183: 613-620 [Abstract] [Full Text]  
• Fancy, S. P.J., Baranzini, S. E., Zhao, C., Yuk, D.-I., Irvine, K.-A., Kaing, S., Sanai, N., Franklin, R. J.M., Rowitch, D. H. (2009). Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 23: 1571-1585 [Abstract] [Full Text]  
• Weinger, J. G., Omari, K. M., Marsden, K., Raine, C. S., Shafit-Zagardo, B. (2009). Up-Regulation of Soluble Axl and Mer Receptor Tyrosine Kinases Negatively Correlates with Gas6 in Established Multiple Sclerosis Lesions. Am. J. Pathol. 175: 283-293 [Abstract] [Full Text]  
• Kroner, A., Schwab, N., Ip, C. W., Ortler, S., Gobel, K., Nave, K.-A., Maurer, M., Martini, R., Wiendl, H. (2009). Accelerated Course of Experimental Autoimmune Encephalomyelitis in PD-1-Deficient Central Nervous System Myelin Mutants. Am. J. Pathol. 174: 2290-2299 [Abstract] [Full Text]  
• Zamboni, P, Galeotti, R, Menegatti, E, Malagoni, A M, Tacconi, G, Dall'Ara, S, Bartolomei, I, Salvi, F (2009). Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 80: 392-399 [Abstract] [Full Text]  
• Fagius, J, Lundgren, J, Oberg, G (2009). Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 15: 229-237 [Abstract]  
• Tedeschi, G, Dinacci, D, Comerci, M, Lavorgna, L, Savettieri, G, Quattrone, A, Livrea, P, Patti, F, Brescia Morra, V, Servillo, G, Orefice, G, Paciello, M, Prinster, A, Coniglio, G, Bonavita, S, Di Costanzo, A, Bellacosa, A, Valentino, P, Quarantelli, M, Brunetti, A, Salemi, G, D'Amelio, M, Simone, I, Salvatore, M, Bonavita, V, Alfano, B (2009). Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study. Mult Scler 15: 204-211 [Abstract]  
• Lu, J.-Q., Storek, J., Metz, L., Yong, V. W., Stevens, A. M., Nash, R. A., Joseph, J. T. (2009). Continued Disease Activity in a Patient With Multiple Sclerosis After Allogeneic Hematopoietic Cell Transplantation. Arch Neurol 66: 116-120 [Abstract] [Full Text]  
• Omari, K. M., Lutz, S. E., Santambrogio, L., Lira, S. A., Raine, C. S. (2009). Neuroprotection and Remyelination after Autoimmune Demyelination in Mice that Inducibly Overexpress CXCL1. Am. J. Pathol. 174: 164-176 [Abstract] [Full Text]  
• Martin, M. d. P., Cravens, P. D., Winger, R., Frohman, E. M., Racke, M. K., Eagar, T. N., Zamvil, S. S., Weber, M. S., Hemmer, B., Karandikar, N. J., Kleinschmidt-DeMasters, B. K., Stuve, O. (2008). Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. Arch Neurol 65: 1596-1603 [Abstract] [Full Text]  
• Lunemann, A., Lunemann, J. D., Roberts, S., Messmer, B., da Silva, R. B., Raine, C. S., Munz, C. (2008). Human NK Cells Kill Resting but Not Activated Microglia via NKG2D- and NKp46-Mediated Recognition. J. Immunol. 181: 6170-6177 [Abstract] [Full Text]  
• Lin, W., Kunkler, P. E., Harding, H. P., Ron, D., Kraig, R. P., Popko, B. (2008). Enhanced Integrated Stress Response Promotes Myelinating Oligodendrocyte Survival in Response to Interferon-{gamma}. Am. J. Pathol. 173: 1508-1517 [Abstract] [Full Text]  
• Racke, M. K. (2008). Editorial: Challenges in developing new multiple sclerosis therapies. Therapeutic Advances in Neurological Disorders 1: 63-65  
• Mostert, J P, Admiraal-Behloul, F, Hoogduin, J M, Luyendijk, J, Heersema, D J, van Buchem, M A, De Keyser, J (2008). Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J. Neurol. Neurosurg. Psychiatry 79: 1027-1031 [Abstract] [Full Text]  
• Wuerfel, J., Haertle, M., Waiczies, H., Tysiak, E., Bechmann, I., Wernecke, K. D., Zipp, F., Paul, F. (2008). Perivascular spaces--MRI marker of inflammatory activity in the brain?. Brain 131: 2332-2340 [Abstract] [Full Text]  
• Kiel, M. E., Chen, C. P., Sadowski, D., McKinnon, R. D. (2008). Stem Cell-Derived Therapeutic Myelin Repair Requires 7% Cell Replacement. Stem Cells 26: 2229-2236 [Abstract] [Full Text]  
• Flores, A. I., Narayanan, S. P., Morse, E. N., Shick, H. E., Yin, X., Kidd, G., Avila, R. L., Kirschner, D. A., Macklin, W. B. (2008). Constitutively Active Akt Induces Enhanced Myelination in the CNS. J. Neurosci. 28: 7174-7183 [Abstract] [Full Text]  
• Mahad, D., Ziabreva, I., Lassmann, H., Turnbull, D. (2008). Mitochondrial defects in acute multiple sclerosis lesions. Brain 131: 1722-1735 [Abstract] [Full Text]  
• Gaupp, S., Cannella, B., Raine, C. S. (2008). Amelioration of Experimental Autoimmune Encephalomyelitis in IL-4R{alpha}-/- Mice Implicates Compensatory Up-Regulation of Th2-Type Cytokines. Am. J. Pathol. 173: 119-129 [Abstract] [Full Text]  
• Fainardi, E., Rizzo, R., Melchiorri, L., Stignani, M., Castellazzi, M., Tamborino, C., Paolino, E., Tola, M., Granieri, E., Baricordi, O. (2008). CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing--remitting multiple sclerosis. Mult Scler 14: 446-454 [Abstract]  
• Frohman, T. C., Galetta, S., Fox, R., Solomon, D., Straumann, D., Filippi, M., Zee, D., Frohman, E. M. (2008). Pearls & Oy-sters: The medial longitudinal fasciculus in ocular motor physiology. Neurology 70: e57-e67 [Abstract] [Full Text]  
• Chen, J. W., Breckwoldt, M. O., Aikawa, E., Chiang, G., Weissleder, R. (2008). Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain 131: 1123-1133 [Abstract] [Full Text]  
• Davis, S. L., Frohman, T. C., Crandall, C. G., Brown, M. J., Mills, D. A., Kramer, P. D., Stuve, O., Frohman, E. M. (2008). Modeling Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis. Neurology 70: 1098-1106 [Abstract] [Full Text]  
• McCandless, E. E., Piccio, L., Woerner, B. M., Schmidt, R. E., Rubin, J. B., Cross, A. H., Klein, R. S. (2008). Pathological Expression of CXCL12 at the Blood-Brain Barrier Correlates with Severity of Multiple Sclerosis. Am. J. Pathol. 172: 799-808 [Abstract] [Full Text]  
• Jurynczyk, M., Jurewicz, A., Raine, C. S., Selmaj, K. (2008). Notch3 Inhibition in Myelin-Reactive T Cells Down-Regulates Protein Kinase C{theta} and Attenuates Experimental Autoimmune Encephalomyelitis. J. Immunol. 180: 2634-2640 [Abstract] [Full Text]  
• Minagar, A., Alexander, J. S., Schwendimann, R. N., Kelley, R. E., Gonzalez-Toledo, E., Jimenez, J. J., Mauro, L., Jy, W., Smith, S. J. (2008). Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial. Arch Neurol 65: 199-204 [Abstract] [Full Text]  
• Frohman, E. M., Costello, F., Stuve, O., Calabresi, P., Miller, D. H., Hickman, S. J., Sergott, R., Conger, A., Salter, A., Krumwiede, K. H., Frohman, T. C., Balcer, L., Zivadinov, R. (2008). Modeling Axonal Degeneration Within the Anterior Visual System: Implications for Demonstrating Neuroprotection in Multiple Sclerosis. Arch Neurol 65: 26-35 [Abstract] [Full Text]  
• Rejdak, K., Petzold, A., Stelmasiak, Z., Giovannoni, G. (2008). Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 14: 59-66 [Abstract]  
• Nessler, S., Boretius, S., Stadelmann, C., Bittner, A., Merkler, D., Hartung, H.-P., Michaelis, T., Bruck, W., Frahm, J., Sommer, N., Hemmer, B. (2007). Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain 130: 2186-2198 [Abstract] [Full Text]  
• Antony, J. M., Ellestad, K. K., Hammond, R., Imaizumi, K., Mallet, F., Warren, K. G., Power, C. (2007). The Human Endogenous Retrovirus Envelope Glycoprotein, Syncytin-1, Regulates Neuroinflammation and Its Receptor Expression in Multiple Sclerosis: A Role for Endoplasmic Reticulum Chaperones in Astrocytes. J. Immunol. 179: 1210-1224 [Abstract] [Full Text]  
• Lunemann, J. D., Kamradt, T., Martin, R., Munz, C. (2007). Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis?. J. Virol. 81: 6777-6784 [Full Text]  
• Ransohoff, R. M. (2007). Natalizumab for Multiple Sclerosis. NEJM 356: 2622-2629 [Full Text]  
• Frohman, E. M., Kerr, D. (2007). Is Neuromyelitis Optica Distinct From Multiple Sclerosis?: Something for "Lumpers" and "Splitters". Arch Neurol 64: 903-905 [Full Text]  
• Roach, E. S. (2007). Is Neuromyelitis Optica a Distinct Entity?. Arch Neurol 64: 906-906 [Full Text]  
• Rossi, C., Padmanaban, D., Ni, J., Yeh, L.-A., Glicksman, M. A., Waldner, H. (2007). Identifying Druglike Inhibitors of Myelin-Reactive T Cells by Phenotypic High-Throughput Screening of a Small-Molecule Library. J Biomol Screen 12: 481-489 [Abstract]  
• Forte, M., Gold, B. G., Marracci, G., Chaudhary, P., Basso, E., Johnsen, D., Yu, X., Fowlkes, J., Rahder, M., Stem, K., Bernardi, P., Bourdette, D. (2007). Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 104: 7558-7563 [Abstract] [Full Text]  
• Lawson, B. R., Manenkova, Y., Ahamed, J., Chen, X., Zou, J.-P., Baccala, R., Theofilopoulos, A. N., Yuan, C. (2007). Inhibition of Transmethylation Down-Regulates CD4 T Cell Activation and Curtails Development of Autoimmunity in a Model System. J. Immunol. 178: 5366-5374 [Abstract] [Full Text]  
• Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., Aloisi, F. (2007). Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089-1104 [Abstract] [Full Text]  
• Benito, C., Romero, J. P., Tolon, R. M., Clemente, D., Docagne, F., Hillard, C. J., Guaza, C., Romero, J. (2007). Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis. J. Neurosci. 27: 2396-2402 [Abstract] [Full Text]  
• Aktas, O., Ullrich, O., Infante-Duarte, C., Nitsch, R., Zipp, F. (2007). Neuronal Damage in Brain Inflammation. Arch Neurol 64: 185-189 [Abstract] [Full Text]  
• Jurewicz, A., Matysiak, M., Raine, C. S., Selmaj, K. (2007). Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 68: 283-287 [Abstract] [Full Text]  
• Kel, J., Oldenampsen, J., Luca, M., Drijfhout, J. W., Koning, F., Nagelkerken, L. (2007). Soluble Mannosylated Myelin Peptide Inhibits the Encephalitogenicity of Autoreactive T Cells during Experimental Autoimmune Encephalomyelitis. Am. J. Pathol. 170: 272-280 [Abstract] [Full Text]  
• Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., Bruck, W., Lucchinetti, C., Lassmann, H. (2006). Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129: 3165-3172 [Abstract] [Full Text]  
• Zhang, Y., Taveggia, C., Melendez-Vasquez, C., Einheber, S., Raine, C. S., Salzer, J. L., Brosnan, C. F., John, G. R. (2006). Interleukin-11 Potentiates Oligodendrocyte Survival and Maturation, and Myelin Formation.. J. Neurosci. 26: 12174-12185 [Abstract] [Full Text]  
• Stuve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., Cook, L., Grand'Maison, F., Hemmer, B., Monson, N. L., Racke, M. K. (2006). Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.. Arch Neurol 63: 1383-1387 [Abstract] [Full Text]  
• Amend, B., Doster, H., Lange, C., Dubois, E., Kalbacher, H., Melms, A., Bischof, F. (2006). Induction of Autoimmunity by Expansion of Autoreactive CD4+CD62Llow Cells In Vivo. J. Immunol. 177: 4384-4390 [Abstract] [Full Text]  
• Gold, R., Hohlfeld, R. (2006). Multiple sclerosis therapy: new agents carry new risks. PN 6: 248-251 [Full Text]  
• (2006). Two-Year Benefit from Natalizumab for MS. JWatch Neurology 2006: 1-1 [Full Text]